Acute injury, such as chemotherapy-induced peripheral neuropathy (CIPN), is a particularly good initial target for a SARM1 inhibitor, as it is a major reason for limiting the doses of chemotherapies, and the neuropathy onsets only after chemotherapy starts (Cashman and Höke, 2015; Simon and Watkins, 2018; Coleman and Höke, 2020; Bosanac et al., 2021). Here, SARM1 is linked to neuropathy.